Vaxcyte, Inc. (NASDAQ:PCVX) Receives $147.50 Consensus PT from Analysts

Shares of Vaxcyte, Inc. (NASDAQ:PCVX) have earned a consensus recommendation of “Buy” from the seven ratings firms that are presently covering the firm, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers that have issued a report on the stock in the last year is $147.50.

Several brokerages have recently commented on PCVX. Jefferies Financial Group raised their target price on Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Leerink Partners lifted their target price on Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research note on Tuesday, September 3rd. Bank of America increased their price target on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Mizuho boosted their price objective on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Finally, BTIG Research increased their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd.

Vaxcyte Trading Down 0.2 %

PCVX stock opened at $87.72 on Thursday. Vaxcyte has a 52 week low of $53.83 and a 52 week high of $121.06. The company has a market capitalization of $10.93 billion, a price-to-earnings ratio of -19.07 and a beta of 0.94. The firm’s 50-day moving average is $101.11 and its two-hundred day moving average is $91.68.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter in the prior year, the company earned ($0.91) EPS. On average, equities research analysts predict that Vaxcyte will post -4.14 earnings per share for the current year.

Insider Activity at Vaxcyte

In related news, CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total transaction of $927,520.00. Following the transaction, the chief financial officer now directly owns 90,383 shares in the company, valued at $10,479,005.02. The trade was a 8.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Grant Pickering sold 7,098 shares of Vaxcyte stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $109.21, for a total value of $775,172.58. Following the sale, the chief executive officer now directly owns 138,581 shares in the company, valued at $15,134,431.01. The trade was a 4.87 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 117,830 shares of company stock worth $12,600,310 in the last 90 days. 3.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Vaxcyte

A number of institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC increased its position in shares of Vaxcyte by 23.1% during the 3rd quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company’s stock worth $1,247,954,000 after purchasing an additional 2,052,989 shares in the last quarter. RA Capital Management L.P. grew its stake in Vaxcyte by 5.9% during the third quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company’s stock worth $992,914,000 after buying an additional 485,436 shares during the last quarter. State Street Corp increased its holdings in shares of Vaxcyte by 1.1% during the third quarter. State Street Corp now owns 3,405,743 shares of the company’s stock worth $389,174,000 after buying an additional 38,596 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of Vaxcyte by 13.2% during the third quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company’s stock worth $315,162,000 after buying an additional 324,560 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Vaxcyte by 10.6% in the third quarter. Geode Capital Management LLC now owns 2,700,782 shares of the company’s stock valued at $308,675,000 after acquiring an additional 259,010 shares during the last quarter. 96.78% of the stock is owned by institutional investors and hedge funds.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.